Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF Treatment for ALS
NCT00397423Phase 2Completed
- Sponsor
- Peking University
- Start
- Dec 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing G-CSF with Placebo (2 arms). Primary endpoint: Mean rate of decline of ALS-Functional Rating Scale score at 12 months. Started Dec 2006; status: completed.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00397423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397423.